Abstract
Drug-induced myasthenia gravis (MG) can be caused by various classes of medications, and many therapeutic agents have been known to interfere directly with neuromuscular transmission by affecting either presynaptic or postsynaptic function.1 Omalizumab is a recombinant DNA-derived humanized immunoglobulin (Ig) G1 monoclonal antibody specifically designed to bind to free human IgE and a membrane-bound form of IgE on B lymphocytes; it is used in the treatment of allergic asthma and chronic urticaria.2 We report a case of omalizumab-induced MG with a positive challenge–rechallenge response.
| Original language | English |
|---|---|
| Pages (from-to) | e630-e632 |
| Number of pages | 3 |
| Journal | Canadian Journal of Ophthalmology |
| Volume | 59 |
| Issue number | 5 |
| Early online date | 14 Apr 2024 |
| DOIs | |
| Publication status | Published - Oct 2024 |
Keywords
- Myasthenia gravis
- Eye
- Omalizumab